Preview Mode Links will not work in preview mode

ISHLT Voices features conversations, studies, and member profiles. Explore advanced heart and lung failure, transplantation, mechanical circulatory support, and pulmonary vascular disease through the eyes of your community.

Dec 15, 2023

Presented by Natera

Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does.

In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.

Headshot of Philip Halloran, wearing a black suit and tie against a textured wood backgroundPhilip F. Halloran, MD, PhD, FRCP(C), OC, FRSC

Professor of Medicine & Medical Microbiology and Immunology
Director, Alberta Transplant Applied Genomics Centre
University of Alberta
Edmonton, AB Canada

A headshot of Kieran Halloran, wearing a grey sport coat against a white backgroundKieran Halloran, MD, MSc

Transplant Pulmonologist
Associate Professor
University of Alberta
Edmonton, AB Canada

A headshot of Patrick Gauthier, wearing a blue jacket and tie in an outdoor settingPatrick Gauthier, PhD

Senior Data Scientist
Alberta Transplant Applied Genomics Centre
Edmonton, AB Canada

 

This episode was created for ISHLT Voices and sponsored by Natera.

Natera corporate logo

The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.